Search

Your search keyword '"Kopp BT"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Kopp BT" Remove constraint Author: "Kopp BT"
81 results on '"Kopp BT"'

Search Results

1. Respiratory syncytial virus: current and emerging treatment options

2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy

4. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

5. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

6. ENaC contributes to macrophage dysfunction in cystic fibrosis.

7. PPARγ/ETV2 axis regulates endothelial-to-mesenchymal transition in pulmonary hypertension.

8. Updates in Pediatric Sickle Cell Lung Disease.

9. Pseudomonas aeruginosa Lipid A Structural Variants Induce Altered Immune Responses.

10. Nasal airway inflammatory responses and pathogen detection in infants with cystic fibrosis.

12. Description of a Colocated Comprehensive Care Model for People With Sickle Cell and Comorbid Pulmonary Disease.

13. Outcomes before and after providing interdisciplinary hematology and pulmonary care for children with sickle cell disease.

14. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.

15. Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.

16. Long-term pulmonary sequelae in adolescents post-SARS-CoV-2 infection.

17. Emerging Concepts in Defective Macrophage Phagocytosis in Cystic Fibrosis.

18. Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor/Tezacaftor/Ivacaftor initiation in a preadolescent with cystic fibrosis.

19. Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.

20. Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial.

21. (R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages.

23. Metabolomics profiling of tobacco exposure in children with cystic fibrosis.

24. Consequences of CRISPR-Cas9-Mediated CFTR Knockout in Human Macrophages.

26. Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis.

27. Baseline and Disease-Induced Transcriptional Profiles in Children with Sickle Cell Disease.

28. Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis.

29. Gastroesophageal reflux in cystic fibrosis across the age spectrum.

30. AR-13 reduces antibiotic-resistant bacterial burden in cystic fibrosis phagocytes and improves cystic fibrosis transmembrane conductance regulator function.

31. Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report.

32. Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosis.

33. Pulmonary findings in infants with cystic fibrosis during the first year of life: Results from the Baby Observational and Nutrition Study (BONUS) cohort study.

34. Cell Therapy for Cystic Fibrosis Lung Disease: Regenerative Basal Cell Amplification.

35. Secondhand smoke alters arachidonic acid metabolism and inflammation in infants and children with cystic fibrosis.

37. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.

38. Impact of Presence of Children on Indoor Tobacco Restrictions in Households of Urban and Rural Adult Tobacco Users.

39. Dysregulated Calcium Homeostasis in Cystic Fibrosis Neutrophils Leads to Deficient Antimicrobial Responses.

40. The expression of Mirc1/Mir17-92 cluster in sputum samples correlates with pulmonary exacerbations in cystic fibrosis patients.

41. Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis.

42. Cysteamine-mediated clearance of antibiotic-resistant pathogens in human cystic fibrosis macrophages.

43. Not All Children with Cystic Fibrosis Have Abnormal Esophageal Neutralization during Chemical Clearance of Acid Reflux.

44. The effect of the affordable care act dependent coverage provision on patients with cystic fibrosis.

45. Transplant center volume and outcomes in lung transplantation for cystic fibrosis.

46. Human Cystic Fibrosis Macrophages Have Defective Calcium-Dependent Protein Kinase C Activation of the NADPH Oxidase, an Effect Augmented by Burkholderia cenocepacia .

47. Pretransplant Panel Reactive Antibodies and Lung Transplant Outcomes in Children.

48. Secondhand Smoke Is an Important Modifiable Risk Factor in Sickle Cell Disease: A Review of the Current Literature and Areas for Future Research.

49. Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages.

50. The Impact of Secondhand Smoke Exposure on Children with Cystic Fibrosis: A Review.

Catalog

Books, media, physical & digital resources